From a pharmacological pharmacy viewpoint, Relafen 750, containing naproxen, represents a fascinating case study in medication action. Its chief mechanism involves blocking cyclooxygenase (COX) enzymes, specifically COX-2, which contributes reduced production of pain signals. This specific inhibition reduces swelling and ache associated with condit